<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">8102137</journal-id><journal-id journal-id-type="pubmed-jr-id">4625</journal-id><journal-id journal-id-type="nlm-ta">J Clin Immunol</journal-id><journal-id journal-id-type="iso-abbrev">J. Clin. Immunol.</journal-id><journal-title-group><journal-title>Journal of clinical immunology</journal-title></journal-title-group><issn pub-type="ppub">0271-9142</issn><issn pub-type="epub">1573-2592</issn></journal-meta><article-meta><article-id pub-id-type="pmid">23744081</article-id><article-id pub-id-type="pmc">3722498</article-id><article-id pub-id-type="doi">10.1007/s10875-013-9913-2</article-id><article-id pub-id-type="manuscript">NIHMS490004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Chitotriosidase is a Biomarker for the Resistance to World Trade Center Lung Injury in New York City Firefighters</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Soo Jung</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Nolan</surname><given-names>Anna</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Echevarria</surname><given-names>Ghislaine C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A4">d</xref><xref ref-type="aff" rid="A5">e</xref></contrib><contrib contrib-type="author"><name><surname>Kwon</surname><given-names>Sophia</given-names></name><degrees>MPH</degrees><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Naveed</surname><given-names>Bushra</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Schenck</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Tsukiji</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Prezant</surname><given-names>David J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A3">c</xref><xref ref-type="aff" rid="A6">f</xref></contrib><contrib contrib-type="author"><name><surname>Rom</surname><given-names>William N.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Weiden</surname><given-names>Michael D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">a</xref><xref ref-type="aff" rid="A2">b</xref><xref ref-type="aff" rid="A3">c</xref></contrib></contrib-group><aff id="A1"><label>a</label>Division of Pulmonary, Critical Care and Sleep, New York University, School of Medicine New York, NY</aff><aff id="A2"><label>b</label>New York University, School of Medicine, Department of Environmental Medicine, Tuxedo Park, NY</aff><aff id="A3"><label>c</label>Bureau of Health Services and Office of Medical Affairs, Fire Department of New York, Brooklyn, NY</aff><aff id="A4"><label>d</label>Divisi&#x000f3;n de Anestesiolog&#x000ed;a, Escuela de Medicina, Pontificia Universidad Cat&#x000f3;lica de Chile - Santiago, Chile</aff><aff id="A5"><label>e</label>New York University Department of Medicine - New York, NY/US</aff><aff id="A6"><label>f</label>Pulmonary Medicine Division, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY</aff><author-notes><corresp id="FN1">Corresponding Author: Michael D. Weiden, MD, Associate Professor of Medicine and Environmental Medicine, New York University School of Medicine, 550 1st Ave, New York, NY 10016, <email>michael.weiden@med.nyu.edu</email>, Phone: 212-263-6479, Fax: 212-263-8442</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>1</day><month>7</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>07</day><month>6</month><year>2013</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>8</month><year>2014</year></pub-date><volume>33</volume><issue>6</issue><fpage>1134</fpage><lpage>1142</lpage><!--elocation-id from pubmed: 10.1007/s10875-013-9913-2--><abstract><sec id="S1"><title>Purpose</title><p id="P1">World Trade Center (WTC) exposure caused airflow obstruction years after exposure. Chitinases and IgE are innate and humoral mediators of obstructive airway disease. We investigated if serum expression of chitinases and IgE early after WTC exposure predicts subsequent obstruction.</p></sec><sec id="S2"><title>Methods</title><p id="P2">With a nested case-control design, 251 FDNY personnel had chitotriosidase, YKL-40 and IgE measured in serum drawn within months of 9/11/2001. The main outcome was subsequent Forced Expiratory Volume after one second/Forced Vital Capacity (FEV<sub>1</sub>/FVC) less than the lower limit of normal (LLN). Cases (N=125) had abnormal FEV<sub>1</sub>/FVC whereas controls had normal FEV<sub>1</sub>/FVC (N=126). In a secondary analysis, resistant cases (N=66) had FEV<sub>1</sub> (&#x02265;107%) one standard deviation above the mean. Logistic regression adjusted for age, BMI, exposure intensity and post-exposure FEV<sub>1</sub>/FVC modeled the association between early biomarkers and later lung function.</p></sec><sec id="S3"><title>Results</title><p id="P3">Cases and Controls initially lost lung function. Controls recovered to pre-9/11 FEV<sub>1</sub> and FVC while cases continue to decline. Cases expressed lower serum chitotriosidase and higher IgE levels. Increase in IgE increased the odds of airflow obstruction and decreased the odds of above average FEV<sub>1</sub>. Alternately, increasing chitotriosidase decreased the odds of abnormal FEV<sub>1</sub>/FVC and increased the odds of FEV<sub>1</sub>&#x02265;107%. Serum YKL-40 was not associated with FEV<sub>1</sub>/FVC or FEV<sub>1</sub> in this cohort.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">Increased serum chitotriosidase reduces the odds of developing obstruction after WTC-particulate matter exposure and is associated with recovery of lung function. Alternately, elevated IgE is a risk factor for airflow obstruction and progressive lung function decline.</p></sec></abstract><kwd-group><kwd>Chitotriosidase</kwd><kwd>Immunoglobulin E</kwd><kwd>WTC Particulate Matter</kwd><kwd>Pulmonary Function Testing</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S5"><title>INTRODUCTION</title><p id="P5">World Trade Center (WTC)-particulate matter (PM) exposure from the 9/11 disaster resulted in significant airflow obstruction and reactive airway disease in Fire Department of New York (FDNY) rescue workers, other exposed workers, lower Manhattan residents and children (<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R7" ref-type="bibr">7</xref>). A recent longitudinal study by FDNY reported that exposure to WTC dust led to a dramatic decline in forced expiratory volume in one second (FEV<sub>1</sub>) of FDNY rescue workers during the first year after exposure without subsequent recovery in a majority of those exposed (<xref rid="R8" ref-type="bibr">8</xref>). A minority of those exposed had accelerated decline of lung function suggesting greater than average susceptibility to lung injury (<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R8" ref-type="bibr">8</xref>). Alternately, another subgroup recovered of FEV<sub>1</sub> suggesting greater than average resistance to the long-term effects of PM exposure (<xref rid="R9" ref-type="bibr">9</xref>). It is unclear why some individuals&#x02019; lung function improved while others&#x02019; continued to deteriorate. We therefore characterized biomarkers of resistance and susceptibility to WTC PM-related lung injury. We previously described a set of biomarkers of inflammation, metabolic syndrome and vascular injury in serum collected within six months of 9/11/2001 that predicted future decline or improvement in FEV<sub>1</sub> (<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>).</p><p id="P6">The ratio of FEV<sub>1</sub>/Forced Vital Capacity (FVC) is another well-validated spirometric measure. Reduction of FEV<sub>1</sub>/FVC indicates airflow obstruction that characterizes COPD and asthma. Genome wide association studies (GWAS) observed that a set of genetic variants are associated with only FEV<sub>1</sub>, variation at other loci predict only FEV<sub>1</sub>/FVC and variation at a third set of loci is associated with both FEV<sub>1</sub> and FEV<sub>1</sub>/FVC (<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R13" ref-type="bibr">13</xref>). This suggests independent but overlapping regulation of FEV<sub>1</sub> and FEV<sub>1</sub>/FVC in health and disease. Biomarkers predicting abnormal FEV<sub>1</sub>/FVC may therefore be distinct from FEV<sub>1</sub>. Hence, we investigated if biomarkers expressed within 6 months of 9/11/2001 predicted future abnormal FEV<sub>1</sub>/FVC in this WTC exposed cohort.</p><p id="P7">The glycosyl hydrolase 18 gene family contains true chitinases that bind and cleave chitin. Other chitinase-like proteins (CLP) bind but do not cleave the chitin polysaccharide. Among these chitinases/CLPs, chitotriosidase is the major enzymatically active chitinase in humans and the best characterized chitinase from a biologic and clinical perspective (<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>). Chitotriosidase is part of the innate host defense against bacterial and fungal infections since chitin is a major structural component in bacteria, fungi, insects and crustaceans, but not in mammals (<xref rid="R16" ref-type="bibr">16</xref>&#x02013;<xref rid="R20" ref-type="bibr">20</xref>). YKL-40 is a CLP that is strongly associated with human diseases characterized by inflammation, remodeling and fibrosis (<xref rid="R21" ref-type="bibr">21</xref>&#x02013;<xref rid="R25" ref-type="bibr">25</xref>). However, its biological function has not been clearly defined. Chitotriosidase is produced in mature monocyte-derived macrophages, lung macrophages and other specific subsets of tissue macrophages (<xref rid="R26" ref-type="bibr">26</xref>&#x02013;<xref rid="R29" ref-type="bibr">29</xref>). Elevated chitotriosidase expression is associated with smoking induced and fibrotic lung disease (<xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R31" ref-type="bibr">31</xref>). The utility of chitotriosidase or YKL-40 as biomarkers of lung disease is under active investigation. However, their utility in particulate matter induced airway obstruction has not been elucidated.</p><p id="P8">Immunoglobulin E (IgE)-mediated humoral immunity is another important immune response mechanism in the respiratory tract (<xref rid="R32" ref-type="bibr">32</xref>). Elevated IgE is a key immune mediator in asthma. Children and adults with asthma have higher IgE than normal controls and anti-IgE antibody is an effective asthma treatment (<xref rid="R33" ref-type="bibr">33</xref>&#x02013;<xref rid="R36" ref-type="bibr">36</xref>). Elevated serum IgE is strongly associated with low FEV<sub>1</sub>/FVC in patients with chronic obstructive lung disease (<xref rid="R37" ref-type="bibr">37</xref>).</p><p id="P9">Our studies have focused on the well phenotyped WTC exposed FDNY firefighter cohort. The intense PM exposure at the WTC site overwhelmed the lung&#x02019;s normal protective barriers. We hypothesized that particulate matter exposure-induced lung injury is associated with immune mediators of asthma and COPD. We tested if serum chitinases and IgE, expressed soon after a massive PM exposure predict subsequent airway obstruction.</p></sec><sec sec-type="methods" id="S6"><title>METHODS</title><sec id="S7"><title>Study design</title><p id="P10">We preformed a nested case-control study using a homogeneous previously healthy baseline cohort of 801 WTC exposed rescue and recovery workers. The study group did not contain individuals with lung disease or tobacco use to eliminate these confounders. The baseline cohort was derived from 1,720 exposed workers who needed subspecialty pulmonary evaluation (SPE) and treatment within 6.5 years of 9/11/2001. The study cohort was derived from three subgroups of the baseline cohort: 1) A randomly selected a subgroup to represent biomarker expression in the total cohort (171/801). 2) Those with the worst FEV<sub>1</sub> at SPE (100/801) to represent those susceptible to WTC induced lung injury. 3) Those with the best FEV<sub>1</sub> at SPE (100/801) to represent those resistant to lung injury (<xref rid="R9" ref-type="bibr">9</xref>). Serum was available in 124/171 of the representative subgroup, 66/100 of the resistant subgroup and 68/100 of the susceptible subgroup. Since there was overlap between subgroups, the study group was 251/801 of the baseline cohort. Cases were defined by FEV<sub>1</sub>/FVC less than lower limit of normal (LLN, N=125) at SPE, whereas controls had FEV<sub>1</sub>/FVC greater than LLN (N=126).</p></sec><sec id="S8"><title>Demographics</title><p id="P11">Age, race and years of service at FDNY were obtained from the FDNY-WTC-monitoring database. BMIs were calculated from height and weight measured at the time of medical monitoring evaluation (MME) and SPE. Degree of exposure was self-reported at the first FDNY-WTC-monitoring and was categorized using the FDNY-WTC Exposure Intensity Index (Arrival Time): i. Presented on the morning of 9/11/2001 ii. Arrived between afternoon on 9/11/2001 and 9/12/2001 (<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>). Those arriving after day three were excluded from analysis as a result of their low numbers in this sample.</p></sec><sec id="S9"><title>Serum Sampling and Analysis</title><p id="P12">Blood drawn at the first post-9/11 FDNY-WTC monitoring exam was allowed to stand for one hour at room temperature before being centrifuged at 1,800g for ten minutes. Serum was stored at &#x02212;80&#x000b0;C (Bio-Reference Laboratories, Inc. Elmwood Park, NJ). Serum was thawed once at four degrees and assayed using chitotriosidase (Quidel, USA), YKL-40 (MicroVue, USA) and IgE (R&#x00026;D, Minnesota, USA) ELISA panels according to manufacturer&#x02019;s instructions. Data was analyzed using Graphpad Prism V (San Diego, USA).</p></sec><sec id="S10"><title>Statistical Analysis</title><p id="P13">We tested normality using the Shapiro-Wilk test and Q-Q plots. We used unpaired Student&#x02019;s t-test or Wilcoxon rank-sum test for between group comparisons, as appropriate. Chi-squared test was used for inferences on proportions.</p><p id="P14">Given the dichotomous outcome of normal and abnormal FEV<sub>1</sub>/FVC ratio, we tested if serum biomarkers predicted airflow obstruction using logistic regression. In addition to demographic variables, we tested if FEV<sub>1</sub>/FVC ratio at the time serum was drawn altered the biomarker disease association. Equivalent analysis was done with the dichotomous outcome of FEV<sub>1</sub>.</p><p id="P15">The Hosmer-Lemeshow goodness-of-fit test was used to assess calibration of the model. The model discrimination was evaluated through the receiver operating characteristic area under the curve (AUC). To test the robustness of the models, internal validation was performed using bootstrap procedures (10,000 bootstrap samples). Data are expressed as mean (standard deviation, SD), median (interquartile range, IQR) or Odds Ratio (95% confidence interval), unless otherwise stated. A two-sided P-value less than 0.05 was considered significant. All analyses were performed with STATA/SE version 12.1 (StataCorp LP, College Station, TX) and SPSS version 20 (IBM, USA).</p></sec></sec><sec sec-type="results" id="S11"><title>Results</title><sec id="S12"><title>Demographics</title><p id="P16">Derivation of cases and controls is described in <xref rid="F1" ref-type="fig">Figure 1</xref>. The demographics of baseline cohort, the study cohort, cases and controls are shown in <xref rid="T1" ref-type="table">Table 1</xref>. A study cohort of 251/801 had biomarkers measured in serum drawn soon after 9/11 during the first medical monitoring exam (MME). The median time to the serum draw at MME was 2.6 months post 9/11. The baseline cohort, study cohort, cases and controls had no significant difference in the time post 9/11 that serum biomarkers were measured.</p><p id="P17">Case status was defined by FEV<sub>1</sub>/FVC ratio at subsequent subspecialty pulmonary evaluation (SPE). Cases of airflow obstruction (125/251) have had an abnormally low FEV<sub>1</sub>/FVC ratio at SPE, while controls (126/251) have a normal ratio. The median time to SPE was 33.8 months post 9/11. The baseline cohort, study cohort, cases and controls had no significant difference in the time post-9/11 that FEV<sub>1</sub>/FVC was measured. Cases and controls had similar WTC exposure intensity, BMI and racial distribution. Cases were two years younger at 9/11 and had 2.2 less years of firefighting service than controls (P&#x0003c;0.01).</p></sec><sec id="S13"><title>Pulmonary Function</title><p id="P18">By design, cases and controls were markedly different from one another in FEV<sub>1</sub>/FVC ratio 34 months after 9/11/2001 on SPE spirometry (0.73 vs 0.82, <xref rid="T2" ref-type="table">Table 2</xref>). Cases and controls were also different from one another in pre-9/11 ratio (0.82 vs 0.87 P&#x0003c;0.001) and ratio at MME (0.81 vs 0.87 P&#x0003c;0.001). In a longitudinal analysis, the FEV<sub>1</sub>/FVC ratio did not change in cases or controls from pre-9/11 spirometry to MME. In the interval from MME to SPE, the ratio declined in both cases (0.81 to 0.73 P&#x0003c;0.001) and controls (0.87 to 0.82 P&#x0003c;0.01) but cases had more deterioration than controls. To confirm that the median FEV<sub>1</sub>/FVC in cases and controls represented individual deterioration, we used patients as their own control subjects. The mean individual reduction of the ratio from 9/11 to SPE was 9% (P=0.019) in cases and 4% in controls (P&#x0003c;0.001).</p><p id="P19">Similar to FEV<sub>1</sub>/FVC ratio, FEV<sub>1</sub> % predicted was consistently lower in cases than controls at all time points. Surprisingly, in longitudinal analysis, cases lost 7% of their pre-9/11 FEV<sub>1</sub> while controls lost 11% at MME. Cases continued to lose FEV<sub>1</sub> from MME to SPE (86% to 81%), whereas FEV<sub>1</sub> in controls increased between two time points (97% to %108) returning to pre-9/11 values. Individual longitudinal lung function demonstrated the mean FEV<sub>1</sub> increased by 5% from 9/11 to SPE in cases (P=0.019) and decreased by 5% in controls (P=0.001). The mean individual FVC increased by 6% in cases (P&#x0003c;0.001) and 8% in controls (P&#x0003c;0.001).</p><p id="P20">At the time of SPE, cases had more air trapping and airway reactivity than controls. Cases had higher residual volume (RV) than controls (130% vs 111% P&#x0003c;0.001) without changes in functional residual capacity (FRC) or diffusing capacity for carbon monoxide (DLCO). Cases had more airway reactivity defined by FEV<sub>1</sub> increase in response to bronchodilator (9, IQR 4&#x02013;16 in cases vs 4, IQR 0&#x02013;8 in controls P&#x0003c;0.001) and FEV<sub>1</sub> decline in response to methacholine (MCT slope of cases 0.092, IQR 0.04&#x02013;0.42 vs controls 0.038, IQR 0.02&#x02013;0.07 P&#x0003c;0.001).</p></sec><sec id="S14"><title>Serum Biomarkers</title><p id="P21">A total of 251 cases and controls had serum chitotriosidase, YKL-40 and IgE measured an average of 3 months after September 11, 2001. Compared to controls, cases had significant reduction of chitotriosidase (24.5ng/mL vs 32.2ng/mL, P&#x0003c;0.001) and significant elevation of IgE (50IU/mL vs 35.7IU/mL, P=0.01) (<xref rid="T3" ref-type="table">Table 3</xref>). There was no difference in YKL-40 between cases and controls (41.0ng/mL vs 44.0ng/mL, P=0.621). The range of chitotriosidase concentration was 1 to 174ng/mL and the range of IgE was 1.47 to 641IU/ml. Since the major source of chitotriosidase is phagocytes, we assessed if controls and cases had different leukocyte concentrations and differentials to rule out confounding effect. There was no significant difference in total leukocyte concentration, absolute neutrophil count and absolute lymphocyte count (P=0.549, 0.942 and 0.057 respectively) between cases and controls.</p></sec><sec id="S15"><title>Logistic model predicting abnormal FEV<sub>1</sub>/FVC</title><p id="P22">In an initial series of univariable analysis we observed significant association of abnormal FEV<sub>1</sub>/FVC ratio at SPE with chitotriosidase, IgE, age and FEV<sub>1</sub>/FVC ratio at the time serum was drawn. Increasing age, chitotriosidase and FEV<sub>1</sub>/FVC ratio at MME reduced the odds of abnormal FEV<sub>1</sub>/FVC ratio at SPE while increasing IgE increased the odds of airflow obstruction (<xref rid="T4" ref-type="table">Table 4</xref>). There was no association between YKL-40 and airflow obstruction (data not shown). In this small cohort, there was no significant association of WTC exposure intensity or BMI with abnormal FEV<sub>1</sub>/FVC ratio at SPE (<xref rid="T4" ref-type="table">Table 4</xref>).</p><p id="P23">Multivariable logistic regression analysis showed that the biomarker-disease association remained after adjusting the model for potential confounders (<xref rid="T4" ref-type="table">Table 4</xref>). For each 10ng/mL increase of serum chitotriosidase the odds airflow obstruction at SPE declined by 18% (95%CI: 0.71, 0.95). We added the range of chitotriosidase to the adjusted logistic model and calculated the probability of abnormal FEV<sub>1</sub>/FVC ratio (<xref rid="F2" ref-type="fig">Figure 2</xref>). When holding all other variables in the model constant the probability of obstruction declined from 60.2% to 15.5% as the concentration of chitotriosidase increased from 1 to 174ng/mL (<xref rid="F2" ref-type="fig">Figure 2</xref> panel A). For each 100IU/mL increase of IgE, the odds of having a FEV<sub>1</sub>/FVC less than LLN increased by 36% (95%CI: 1.09, 1.71). The probability of obstruction increased from 44.8% to 74.9% as the concentration of IgE increased from 1.47 to 641IU/mL (<xref rid="F2" ref-type="fig">Figure 2</xref> panel B). We then used receiver operating characteristic analysis to assess the sensitivity and specificity of the model for predicting airflow obstruction. The model had excellent performance with an AUC of 0.86 (<xref rid="F2" ref-type="fig">Figure 2</xref> panel C). The interaction term between chitotriosidase and IgE was not significant (data not shown).</p></sec><sec id="S16"><title>FEV<sub>1</sub> as an outcome</title><p id="P24">FEV<sub>1</sub> is another well-validated spirometric measure to identify airway obstruction (<xref rid="R9" ref-type="bibr">9</xref>). We repeated the analysis with 66 individuals who had FEV<sub>1</sub>&#x02265;107% at SPE. These cases represent individuals with above average lung function who were resistant to the damaging effects of WTC exposure. We have previously reported the demographics and PFT of these resistant cases (<xref rid="R9" ref-type="bibr">9</xref>). Resistant cases had higher chitotriosidase than controls (26.2ng/mL vs 35.3ng/mL, P=0.007) and significant reduction of IgE (50.0IU/mL vs 35.7IU/mL, P=0.026). There was no difference in YKL-40 between cases and controls (43.2ng/mL vs 41.8ng/mL, P=0.621). For each 10ng/mL increase of serum chitotriosidase the odds of being in resistant group at SPE increased by 14% (95%CI: 1.012, 1.292). There was no association between YKL-40 and improvement in lung function after WTC exposure (95% CI: 0.991, 1.009). For each 100 IU increase in IgE the OR for resistance was 0.887 (95% CI: 0.71, 1.11). In addition, we tested if previously reported biomarkers of FEV<sub>1</sub> (<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>) were correlated with chitotriosidase or IgE. There was significant correlation between chitotriosidase and soluble vascular cell adhesion molecule (sVCAM) (R=0.197, P=0.002). Macrophage-derived chemokine (MDC), granulocyte-macrophage colony-stimulating factor (GM-CSF), leptin, amylin, ApoAII, C-reactive protein (CRP), mMacrophage inflammatory protein (MIP) were not associated with either chitotriosidase or IgE.</p></sec></sec><sec sec-type="discussion" id="S17"><title>DISCUSSION</title><p id="P25">The WTC collapse produced a massive acute exposure to PM leading to a 439mL reduction of FEV<sub>1</sub> over the first six months in never smoking firefighters (<xref rid="R8" ref-type="bibr">8</xref>). FVC declined in parallel producing a pseudo-restrictive pattern on spirometry that was due to air trapping (<xref rid="R38" ref-type="bibr">38</xref>). Some individuals recovered while others had progressive lung function decline. To better understand intrinsic susceptibility and resistance to the damaging effects of WTC exposure we conducted a series of nested case-control studies (<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>). The study cohort was 801 never smokers with normal pre-9/11 lung function who sought subspecialty pulmonary evaluation (SPE) prior to March 2008. We have reported that levels of serum biomarkers of inflammation, metabolic syndrome and cardiovascular risk expressed within 6 months of September 11, 2011 were associated with increased risk of abnormal FEV<sub>1</sub> years later, with higher levels of some associated with increased risk and others associated with reduced risk. We now report early elevation of serum chitotriosidase reduces the risk of airway obstruction defined by abnormal FEV<sub>1</sub>/FVC. It also predicts above average FEV<sub>1</sub> in the years following WTC exposure. Therefore chitotriosidase is a biomarker of resistance to lung injury. Alternately elevated IgE is a risk factor for abnormal FEV<sub>1</sub>/FVC and reduces the odds of above average lung function post WTC exposure. Finally, there was no association of YKL-40 and any measure of lung function. This suggests that YKL-40 regulation in PM-induced asthma is significantly different than YKL-40 in allergic asthma (<xref rid="R21" ref-type="bibr">21</xref>&#x02013;<xref rid="R25" ref-type="bibr">25</xref>).</p><p id="P26">The study cohort was nested within a larger, longitudinally followed population of symptomatic FDNY firefighters who were exposed to particulate matter from the WTC disaster. We narrowed 1720 subjects to a baseline cohort of 801 individuals. We chose to exclude active and prior smokers to eliminate a major confounder of abnormal lung function and chitotriosidase expression (<xref rid="R30" ref-type="bibr">30</xref>).</p><p id="P27">This investigation used FEV<sub>1</sub>/FVC and FEV<sub>1</sub> as two separate outcomes in the analysis. We chose FEV<sub>1</sub>/FVC below LLN to define lung injury since this cut point is derived from large cross sectional population studies. We chose FEV<sub>1</sub>&#x02265;107% to define resistance to lung injury since this value is one standard deviation above the mean at SPE in this WTC exposed cohort. Prior studies of this cohort used only FEV<sub>1</sub> as a measure of susceptibility or resistance to lung injury. Adding an explicit measure of airflow obstruction to the analysis enabled us to overcome the limitations of using of FEV<sub>1</sub> as a single measure of lung injury in this cohort. Using only FEV<sub>1</sub> can result in misclassification of disease since FEV<sub>1</sub> is reduced in both restrictive and obstructive lung disease. Furthermore patients who starting with pre-9/11 FEV<sub>1</sub> well above 107%, could suffer large, clinically significant decline in FEV<sub>1</sub> and remain above the cut point defining resistance to lung injury. Therefore FEV<sub>1</sub>/FVC, when used in conjunction with FEV<sub>1</sub>, provides a more complete measure of the resistance and susceptibility to the damaging effects of WTC exposure.</p><p id="P28">Both serum chitotriosidase and IgE expressed early after exposure are biomarkers for abnormal FEV<sub>1</sub>/FVC and above average FEV<sub>1</sub> years later. The concept that FEV<sub>1</sub>/FVC and FEV<sub>1</sub> may reflect distinct but overlapping pathophysiologic mechanisms of lung disease is supported by GWAS findings (<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R13" ref-type="bibr">13</xref>). Some genetic polymorphisms are associated with both FEV<sub>1</sub> and FEV<sub>1</sub>/FVC, whereas other variants are associated with one or the other. To date chitotriosidase and IgE are the only biomarkers that predict susceptibility or resistance to FEV<sub>1</sub>/FVC. Previously reported biomarkers of FEV<sub>1</sub>(<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>); MDC, GM-CSF, leptin, amylin and apolipoproteins are not associated with airflow obstruction.</p><p id="P29">Patients with normal FEV<sub>1</sub>/FVC and above average FEV<sub>1</sub> years after WTC exposure had higher serum chitotriosidase than controls. Multivariable logistic regression showed that patients with increased serum chitotriosidase soon after exposure had significantly reduced odds of subsequent airflow obstruction defined by abnormal FEV<sub>1</sub>/FVC. They also had increased odds of above average FEV<sub>1</sub>. In fact, these resistant individuals returned to their pre-9/11 FEV<sub>1</sub> and FVC on average 32 months post-9/11. Chitotriosidase is therefore a biomarker of recovery from lung injury. This suggests the group with high chitotriosidase levels had the capacity to repair irritant induced lung injury. We have previously observed sVCAM also predicts average FEV<sub>1</sub>. Interestingly sVCAM expression and chitotriosidase expression are correlated raising the possibility that they are separate components of protective pathways.</p><p id="P30">Our nested case-control biomarker study has the advantage that serum biomarkers were measured on average 3 months after the acute exposure during the process of disease evolution. The outcome occurred on average 32 months after exposure. Because the biomarkers were measured prior to case definition it is unlikely that its expression is a consequence of good outcome. Chitotriosidase plays an important role in innate immunity and is associated with smoking, sarcoidosis, pulmonary infections, as well as interstitial lung disease (<xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R39" ref-type="bibr">39</xref>&#x02013;<xref rid="R42" ref-type="bibr">42</xref>). These cross sectional studies are unable to distinguish if elevated chitotriosidase cause disease, are a reparative response to disease or are a consequence of disease with no impact on lung function. The potential mechanism of chitotriosidase&#x02019;s role in protecting from WTC-PM induced lung injury is unknown. Our data are consistent with the hypothesis that chitotriosidase plays a beneficial role in injury repair after WTC-PM induced lung. Testing this hypothesis requires experiments in model systems in combination with larger longitudinal studies.</p><p id="P31">In contrast to chitotriosidase, IgE is critical for humoral immune function in the lung. IgE&#x02019;s association with airway obstruction and atopy is well known (<xref rid="R32" ref-type="bibr">32</xref>&#x02013;<xref rid="R37" ref-type="bibr">37</xref>). As expected, increased IgE predicted subsequent airway obstruction in our WTC exposed cohort. We also observed that increasing IgE reduced the odds of above average FEV<sub>1</sub> post exposure. Importantly, no member of this cohort had atopic asthma prior to exposure since the presence of asthma precludes active firefighting duty. Also most of the population had IgE levels in the normal range. IgE&#x02019;s association with WTC-PM induced lung injury implies a complex pathophysiologic response to irritant induced lung injury reflected in the humoral immune system. Further investigation is required to assess if antigen specific antibodies are responsible for the observed phenotype or variation of IgE within the normal range reflects other attributes of the immune response to respiratory irritants that increases the risk for lung injury.</p><p id="P32">This study has several limitations. Our FDNY firefighters cohort is unique as they had massive acute exposure to WTC dusts. This limits the generalizability of these finding to other study populations with lower level PM exposure produced by ambient air pollution. We did not have an unexposed control group to compare and therefore we could not determine the direct effect of WTC-PM exposure on chitotriosidase or IgE levels. Replication of these findings in other longitudinally followed populations with and without PM exposure will be important to demonstrate the generalizability of these findings.</p><p id="P33">In this study, increased serum chitotriosidase levels reduced the risk of developing airway obstruction after WTC-PM exposure and predicted above average FEV<sub>1</sub> post exposure. Alternately, elevated IgE was a risk factor for abnormal FEV<sub>1</sub>/FVC and reduced the odds of above average FEV<sub>1</sub>. These results suggest that both innate and humoral immune mediators are involved in the pathogenesis of WTC-PM mediated lung injury. Further investigation is required to define if chitotriosidase is a mediator of lung repair after PM exposure.</p></sec></body><back><ack id="S18"><p><bold>Funding</bold>: K23HL084191 (AN), K24A1080298 (MDW), RO1HL057879; (MDW), HL090316, Al080298A, TL1RR029892; T32 ES007267 (BN, SJC); U01CA008617, RO1HL090316 (WNR), NIOSH/CDC (U10-OH008243, U10-OH008242), and 1 UL1RR029893. This work was also partially funded by the NYU-HHC Clinical and Translational Science Institute, supported in part by grant UL1TR000038 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The funding agencies did not participate in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.</p></ack><fn-group><fn id="FN2" fn-type="con"><p><bold>Author Contributions:</bold> conception and design, S.J.C, M.D.W., and A.N; analysis and interpretation, S.J.C., M.D.W., G.C.E., A.N., S.K.; drafting the manuscript for important intellectual content, S.J.C., M.D.W., A.N., S.K., E.S., J.T., D.J.P., W.N.R.</p></fn><fn id="FN3" fn-type="conflict"><p><bold>Disclosures:</bold> The authors of this manuscript have no actual or potential conflicts of interest to disclose.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prezant</surname><given-names>DJ</given-names></name><name><surname>Weiden</surname><given-names>M</given-names></name><name><surname>Banauch</surname><given-names>GI</given-names></name><name><surname>McGuinness</surname><given-names>G</given-names></name><name><surname>Rom</surname><given-names>WN</given-names></name><name><surname>Aldrich</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Cough and bronchial responsiveness in firefighters at the World Trade Center site</article-title><source>The New England journal of medicine</source><year>2002</year><month>9</month><day>12</day><volume>347</volume><issue>11</issue><fpage>806</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">12226151</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banauch</surname><given-names>GI</given-names></name><name><surname>Dhala</surname><given-names>A</given-names></name><name><surname>Alleyne</surname><given-names>D</given-names></name><name><surname>Alva</surname><given-names>R</given-names></name><name><surname>Santhyadka</surname><given-names>G</given-names></name><name><surname>Krasko</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bronchial hyperreactivity and other inhalation lung injuries in rescue/recovery workers after the World Trade Center collapse</article-title><source>Critical care medicine</source><year>2005</year><month>1</month><volume>33</volume><issue>1 Suppl</issue><fpage>S102</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15640671</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banauch</surname><given-names>GI</given-names></name><name><surname>Hall</surname><given-names>C</given-names></name><name><surname>Weiden</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>HW</given-names></name><name><surname>Aldrich</surname><given-names>TK</given-names></name><name><surname>Christodoulou</surname><given-names>V</given-names></name><etal/></person-group><article-title>Pulmonary function after exposure to the World Trade Center collapse in the New York City Fire Department</article-title><source>American journal of respiratory and critical care medicine</source><year>2006</year><month>8</month><day>1</day><volume>174</volume><issue>3</issue><fpage>312</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16645172</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>DM</given-names></name><name><surname>Baron</surname><given-names>SL</given-names></name><name><surname>Bernard</surname><given-names>BP</given-names></name><name><surname>Lushniak</surname><given-names>BD</given-names></name><name><surname>Banauch</surname><given-names>G</given-names></name><name><surname>Arcentales</surname><given-names>N</given-names></name><etal/></person-group><article-title>Symptoms, respirator use, and pulmonary function changes among New York City firefighters responding to the World Trade Center disaster</article-title><source>Chest</source><year>2004</year><month>4</month><volume>125</volume><issue>4</issue><fpage>1256</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">15078732</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banauch</surname><given-names>GI</given-names></name><name><surname>Alleyne</surname><given-names>D</given-names></name><name><surname>Sanchez</surname><given-names>R</given-names></name><name><surname>Olender</surname><given-names>K</given-names></name><name><surname>Cohen</surname><given-names>HW</given-names></name><name><surname>Weiden</surname><given-names>M</given-names></name><etal/></person-group><article-title>Persistent hyperreactivity and reactive airway dysfunction in firefighters at the World Trade Center</article-title><source>American journal of respiratory and critical care medicine</source><year>2003</year><month>7</month><day>1</day><volume>168</volume><issue>1</issue><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">12615613</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reibman</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Hwang</surname><given-names>SA</given-names></name><name><surname>Gulati</surname><given-names>M</given-names></name><name><surname>Bowers</surname><given-names>JA</given-names></name><name><surname>Rogers</surname><given-names>L</given-names></name><etal/></person-group><article-title>The World Trade Center residents&#x02019; respiratory health study: new-onset respiratory symptoms and pulmonary function</article-title><source>Environmental health perspectives</source><year>2005</year><month>4</month><volume>113</volume><issue>4</issue><fpage>406</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">15811830</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><collab>(CDC) CfDCaP</collab><article-title>Self-reported increase in asthma severity after the September 11 attacks on the World Trade Center-Manhattan, New York</article-title><source>JAMA</source><year>2002</year><volume>288</volume><issue>12</issue><fpage>1466</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12353503</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldrich</surname><given-names>TK</given-names></name><name><surname>Gustave</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>CB</given-names></name><name><surname>Cohen</surname><given-names>HW</given-names></name><name><surname>Webber</surname><given-names>MP</given-names></name><name><surname>Zeig-Owens</surname><given-names>R</given-names></name><etal/></person-group><article-title>Lung function in rescue workers at the World Trade Center after 7 years</article-title><source>The New England journal of medicine</source><year>2010</year><month>4</month><day>8</day><volume>362</volume><issue>14</issue><fpage>1263</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">20375403</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiden</surname><given-names>MD</given-names></name><name><surname>Naveed</surname><given-names>B</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Jung Cho</surname><given-names>S</given-names></name><name><surname>Comfort</surname><given-names>AL</given-names></name><name><surname>Prezant</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Cardiovascular disease biomarkers predict susceptibility or resistance to lung injury in World Trade Center dust exposed firefighters</article-title><source>The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology</source><year>2012</year><month>8</month><day>16</day></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolan</surname><given-names>A</given-names></name><name><surname>Naveed</surname><given-names>B</given-names></name><name><surname>Comfort</surname><given-names>AL</given-names></name><name><surname>Ferrier</surname><given-names>N</given-names></name><name><surname>Hall</surname><given-names>CB</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inflammatory biomarkers predict airflow obstruction after exposure to World Trade Center dust</article-title><source>Chest</source><year>2012</year><month>8</month><volume>142</volume><issue>2</issue><fpage>412</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21998260</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naveed</surname><given-names>B</given-names></name><name><surname>Weiden</surname><given-names>MD</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Gracely</surname><given-names>EJ</given-names></name><name><surname>Comfort</surname><given-names>AL</given-names></name><name><surname>Ferrier</surname><given-names>N</given-names></name><etal/></person-group><article-title>Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study</article-title><source>American journal of respiratory and critical care medicine</source><year>2012</year><month>2</month><day>15</day><volume>185</volume><issue>4</issue><fpage>392</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22095549</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seibold</surname><given-names>MA</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Solon</surname><given-names>M</given-names></name><name><surname>Innes</surname><given-names>A</given-names></name><name><surname>Woodruff</surname><given-names>PG</given-names></name><name><surname>Boot</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit</article-title><source>The Journal of allergy and clinical immunology</source><year>2008</year><month>11</month><volume>122</volume><issue>5</issue><fpage>944</fpage><lpage>50</lpage><fpage>e3</fpage><pub-id pub-id-type="pmid">18845328</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aminuddin</surname><given-names>F</given-names></name><name><surname>Akhabir</surname><given-names>L</given-names></name><name><surname>Stefanowicz</surname><given-names>D</given-names></name><name><surname>Pare</surname><given-names>PD</given-names></name><name><surname>Connett</surname><given-names>JE</given-names></name><name><surname>Anthonisen</surname><given-names>NR</given-names></name><etal/></person-group><article-title>Genetic association between human chitinases and lung function in COPD</article-title><source>Human genetics</source><year>2012</year><month>7</month><volume>131</volume><issue>7</issue><fpage>1105</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">22200767</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussink</surname><given-names>AP</given-names></name><name><surname>Speijer</surname><given-names>D</given-names></name><name><surname>Aerts</surname><given-names>JM</given-names></name><name><surname>Boot</surname><given-names>RG</given-names></name></person-group><article-title>Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases</article-title><source>Genetics</source><year>2007</year><month>10</month><volume>177</volume><issue>2</issue><fpage>959</fpage><lpage>70</lpage><comment>Epub 2007/08/28. eng</comment><pub-id pub-id-type="pmid">17720922</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funkhouser</surname><given-names>JD</given-names></name><name><surname>Aronson</surname><given-names>NN</given-names><suffix>Jr</suffix></name></person-group><article-title>Chitinase family GH18: evolutionary insights from the genomic history of a diverse protein family</article-title><source>BMC Evol Biol</source><year>2007</year><volume>7</volume><fpage>96</fpage><comment>Epub 2007/06/28. eng</comment><pub-id pub-id-type="pmid">17594485</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>AC</given-names></name><name><surname>Souto-Padron</surname><given-names>T</given-names></name><name><surname>de Souza</surname><given-names>W</given-names></name></person-group><article-title>Cytochemical localization of carbohydrate residues in microfilariae of Wuchereria bancrofti and Brugia malayi</article-title><source>The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society</source><year>1993</year><month>4</month><volume>41</volume><issue>4</issue><fpage>571</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8450196</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debono</surname><given-names>M</given-names></name><name><surname>Gordee</surname><given-names>RS</given-names></name></person-group><article-title>Antibiotics that inhibit fungal cell wall development</article-title><source>Annual review of microbiology</source><year>1994</year><volume>48</volume><fpage>471</fpage><lpage>97</lpage></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuhrman</surname><given-names>JA</given-names></name><name><surname>Piessens</surname><given-names>WF</given-names></name></person-group><article-title>Chitin synthesis and sheath morphogenesis in Brugia malayi microfilariae</article-title><source>Molecular and biochemical parasitology</source><year>1985</year><month>10</month><volume>17</volume><issue>1</issue><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">3932852</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neville</surname><given-names>AC</given-names></name><name><surname>Parry</surname><given-names>DA</given-names></name><name><surname>Woodhead-Galloway</surname><given-names>J</given-names></name></person-group><article-title>The chitin crystallite in arthropod cuticle</article-title><source>Journal of cell science</source><year>1976</year><month>6</month><volume>21</volume><issue>1</issue><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">932111</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahabuddin</surname><given-names>M</given-names></name><name><surname>Kaslow</surname><given-names>DC</given-names></name></person-group><article-title>Plasmodium: parasite chitinase and its role in malaria transmission</article-title><source>Experimental parasitology</source><year>1994</year><month>8</month><volume>79</volume><issue>1</issue><fpage>85</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7914174</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Possick</surname><given-names>JD</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Nicolae</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function</article-title><source>The New England journal of medicine</source><year>2008</year><month>4</month><day>17</day><volume>358</volume><issue>16</issue><fpage>1682</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">18403759</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chupp</surname><given-names>GL</given-names></name><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Jarjour</surname><given-names>N</given-names></name><name><surname>Shim</surname><given-names>YM</given-names></name><name><surname>Holm</surname><given-names>CT</given-names></name><name><surname>He</surname><given-names>S</given-names></name><etal/></person-group><article-title>A chitinase-like protein in the lung and circulation of patients with severe asthma</article-title><source>The New England journal of medicine</source><year>2007</year><month>11</month><day>15</day><volume>357</volume><issue>20</issue><fpage>2016</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">18003958</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname><given-names>MH</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy</article-title><source>American journal of respiratory and critical care medicine</source><year>2009</year><month>3</month><day>15</day><volume>179</volume><issue>6</issue><fpage>449</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">19106306</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Elias</surname><given-names>JA</given-names></name></person-group><article-title>Role of breast regression protein-39/YKL-40 in asthma and allergic responses</article-title><source>Allergy, asthma &#x00026; immunology research</source><year>2010</year><month>1</month><volume>2</volume><issue>1</issue><fpage>20</fpage><lpage>7</lpage></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Dela Cruz</surname><given-names>CS</given-names></name><name><surname>Herzog</surname><given-names>E</given-names></name><name><surname>Rosenberg</surname><given-names>SM</given-names></name><name><surname>Ahangari</surname><given-names>F</given-names></name><name><surname>Elias</surname><given-names>JA</given-names></name></person-group><article-title>YKL-40, a chitinase-like protein at the intersection of inflammation and remodeling</article-title><source>American journal of respiratory and critical care medicine</source><year>2012</year><month>4</month><day>1</day><volume>185</volume><issue>7</issue><fpage>692</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">22467800</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Rosa</surname><given-names>M</given-names></name><name><surname>Musumeci</surname><given-names>M</given-names></name><name><surname>Scuto</surname><given-names>A</given-names></name><name><surname>Musumeci</surname><given-names>S</given-names></name><name><surname>Malaguarnera</surname><given-names>L</given-names></name></person-group><article-title>Effect of interferon-gamma, interleukin-10, lipopolysaccharide and tumor necrosis factor-alpha on chitotriosidase synthesis in human macrophages</article-title><source>Clinical chemistry and laboratory medicine: CCLM/FESCC</source><year>2005</year><volume>43</volume><issue>5</issue><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">15899671</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaguarnera</surname><given-names>L</given-names></name><name><surname>Musumeci</surname><given-names>M</given-names></name><name><surname>Di Rosa</surname><given-names>M</given-names></name><name><surname>Scuto</surname><given-names>A</given-names></name><name><surname>Musumeci</surname><given-names>S</given-names></name></person-group><article-title>Interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide promote chitotriosidase gene expression in human macrophages</article-title><source>Journal of clinical laboratory analysis</source><year>2005</year><volume>19</volume><issue>3</issue><fpage>128</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15900564</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renkema</surname><given-names>GH</given-names></name><name><surname>Boot</surname><given-names>RG</given-names></name><name><surname>Muijsers</surname><given-names>AO</given-names></name><name><surname>Donker-Koopman</surname><given-names>WE</given-names></name><name><surname>Aerts</surname><given-names>JM</given-names></name></person-group><article-title>Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins</article-title><source>The Journal of biological chemistry</source><year>1995</year><month>2</month><day>3</day><volume>270</volume><issue>5</issue><fpage>2198</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">7836450</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Eijk</surname><given-names>M</given-names></name><name><surname>van Roomen</surname><given-names>CP</given-names></name><name><surname>Renkema</surname><given-names>GH</given-names></name><name><surname>Bussink</surname><given-names>AP</given-names></name><name><surname>Andrews</surname><given-names>L</given-names></name><name><surname>Blommaart</surname><given-names>EF</given-names></name><etal/></person-group><article-title>Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity</article-title><source>International immunology</source><year>2005</year><month>11</month><volume>17</volume><issue>11</issue><fpage>1505</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">16214810</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agapov</surname><given-names>E</given-names></name><name><surname>Battaile</surname><given-names>JT</given-names></name><name><surname>Tidwell</surname><given-names>R</given-names></name><name><surname>Hachem</surname><given-names>R</given-names></name><name><surname>Patterson</surname><given-names>GA</given-names></name><name><surname>Pierce</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Macrophage chitinase 1 stratifies chronic obstructive lung disease</article-title><source>American journal of respiratory cell and molecular biology</source><year>2009</year><month>10</month><volume>41</volume><issue>4</issue><fpage>379</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">19491341</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letuve</surname><given-names>S</given-names></name><name><surname>Kozhich</surname><given-names>A</given-names></name><name><surname>Humbles</surname><given-names>A</given-names></name><name><surname>Brewah</surname><given-names>Y</given-names></name><name><surname>Dombret</surname><given-names>MC</given-names></name><name><surname>Grandsaigne</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation</article-title><source>The American journal of pathology</source><year>2010</year><month>2</month><volume>176</volume><issue>2</issue><fpage>638</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">20042671</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Bleecker</surname><given-names>ER</given-names></name><name><surname>Amelung</surname><given-names>PJ</given-names></name><name><surname>Holroyd</surname><given-names>KJ</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Panhuysen</surname><given-names>CI</given-names></name><etal/></person-group><article-title>Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy</article-title><source>The New England journal of medicine</source><year>1995</year><month>10</month><day>5</day><volume>333</volume><issue>14</issue><fpage>894</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">7666875</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Ksoll</surname><given-names>M</given-names></name><name><surname>Buhl</surname><given-names>R</given-names></name></person-group><article-title>Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals</article-title><source>The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology</source><year>2000</year><month>10</month><volume>16</volume><issue>4</issue><fpage>609</fpage><lpage>14</lpage></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sears</surname><given-names>MR</given-names></name><name><surname>Burrows</surname><given-names>B</given-names></name><name><surname>Flannery</surname><given-names>EM</given-names></name><name><surname>Herbison</surname><given-names>GP</given-names></name><name><surname>Hewitt</surname><given-names>CJ</given-names></name><name><surname>Holdaway</surname><given-names>MD</given-names></name></person-group><article-title>Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children</article-title><source>The New England journal of medicine</source><year>1991</year><month>10</month><day>10</day><volume>325</volume><issue>15</issue><fpage>1067</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">1891008</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Morgan</surname><given-names>WJ</given-names></name><name><surname>Gergen</surname><given-names>PJ</given-names></name><name><surname>Mitchell</surname><given-names>HE</given-names></name><name><surname>Gern</surname><given-names>JE</given-names></name><name><surname>Liu</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children</article-title><source>The New England journal of medicine</source><year>2011</year><month>3</month><day>17</day><volume>364</volume><issue>11</issue><fpage>1005</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">21410369</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanania</surname><given-names>NA</given-names></name><name><surname>Alpan</surname><given-names>O</given-names></name><name><surname>Hamilos</surname><given-names>DL</given-names></name><name><surname>Condemi</surname><given-names>JJ</given-names></name><name><surname>Reyes-Rivera</surname><given-names>I</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial</article-title><source>Annals of internal medicine</source><year>2011</year><month>5</month><day>3</day><volume>154</volume><issue>9</issue><fpage>573</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">21536936</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renkema</surname><given-names>TE</given-names></name><name><surname>Kerstjens</surname><given-names>HA</given-names></name><name><surname>Schouten</surname><given-names>JP</given-names></name><name><surname>Vonk</surname><given-names>JM</given-names></name><name><surname>Koeter</surname><given-names>GH</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name></person-group><article-title>The importance of serum IgE for level and longitudinal change in airways hyperresponsiveness in COPD</article-title><source>Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology</source><year>1998</year><month>10</month><volume>28</volume><issue>10</issue><fpage>1210</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9824387</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiden</surname><given-names>MD</given-names></name><name><surname>Ferrier</surname><given-names>N</given-names></name><name><surname>Nolan</surname><given-names>A</given-names></name><name><surname>Rom</surname><given-names>WN</given-names></name><name><surname>Comfort</surname><given-names>A</given-names></name><name><surname>Gustave</surname><given-names>J</given-names></name><etal/></person-group><article-title>Obstructive airways disease with air trapping among firefighters exposed to World Trade Center dust</article-title><source>Chest</source><year>2010</year><month>3</month><volume>137</volume><issue>3</issue><fpage>566</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">19820077</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bargagli</surname><given-names>E</given-names></name><name><surname>Maggiorelli</surname><given-names>C</given-names></name><name><surname>Rottoli</surname><given-names>P</given-names></name></person-group><article-title>Human chitotriosidase: a potential new marker of sarcoidosis severity</article-title><source>Respiration; international review of thoracic diseases</source><year>2008</year><volume>76</volume><issue>2</issue><fpage>234</fpage><lpage>8</lpage></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bargagli</surname><given-names>E</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Maggiorelli</surname><given-names>C</given-names></name><name><surname>Di Sipio</surname><given-names>P</given-names></name><name><surname>Margollicci</surname><given-names>M</given-names></name><name><surname>Bianchi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Human Chitotriosidase: a Sensitive Biomarker of Sarcoidosis</article-title><source>Journal of clinical immunology</source><year>2012</year><month>8</month><day>10</day></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Herzog</surname><given-names>EL</given-names></name><name><surname>Ahangari</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Gulati</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-beta1 signaling</article-title><source>Journal of immunology</source><year>2012</year><month>9</month><day>1</day><volume>189</volume><issue>5</issue><fpage>2635</fpage><lpage>44</lpage></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labadaridis</surname><given-names>I</given-names></name><name><surname>Dimitriou</surname><given-names>E</given-names></name><name><surname>Theodorakis</surname><given-names>M</given-names></name><name><surname>Kafalidis</surname><given-names>G</given-names></name><name><surname>Velegraki</surname><given-names>A</given-names></name><name><surname>Michelakakis</surname><given-names>H</given-names></name></person-group><article-title>Chitotriosidase in neonates with fungal and bacterial infections</article-title><source>Archives of disease in childhood Fetal and neonatal edition</source><year>2005</year><month>11</month><volume>90</volume><issue>6</issue><fpage>F531</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">16244214</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study design. WTC=World Trade Center; FDNY=Fire Department City of New York; NHANES=National Health and Nutrition Examination Survey; PFT=Pulmonary Function Test</p></caption><graphic xlink:href="nihms490004f1"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Final logistic model prediction A. Calculated probability of FEV<sub>1</sub>/FVC&#x0003c;LLN with 95% CI as the concentration of chitotriosidase increased over the observed biomarker range with all other covariates held constant. B. Calculated probability of FEV<sub>1</sub>/FVC&#x0003c;LLN as IgE increases C. Receiver operating characteristic (ROC) of the final model to predict abnormal FEV<sub>1</sub>/FVC. Area under the curve (AUC)=0.86.</p></caption><graphic xlink:href="nihms490004f2"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographics</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1"/><th valign="middle" align="left" rowspan="1" colspan="1">Baseline Cohort N=801</th><th valign="middle" align="left" rowspan="1" colspan="1">Study Group N=251</th><th valign="middle" align="left" rowspan="1" colspan="1">Controls N=126</th><th valign="middle" align="left" rowspan="1" colspan="1">Cases N=125</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">High WTC Exposure<xref rid="TFN2" ref-type="table-fn">*</xref><xref rid="TFN4" ref-type="table-fn">&#x02021;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">197 (25)</td><td align="left" valign="top" rowspan="1" colspan="1">52 (21)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (24)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (18)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Intermediate WTC Exposure<xref rid="TFN3" ref-type="table-fn">&#x02020;</xref><xref rid="TFN4" ref-type="table-fn">&#x02021;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">604 (75)</td><td align="left" valign="top" rowspan="1" colspan="1">199 (79)</td><td align="left" valign="top" rowspan="1" colspan="1">96 (76)</td><td align="left" valign="top" rowspan="1" colspan="1">103 (82)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Months to MME<xref rid="TFN5" ref-type="table-fn">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">2.7 (2&#x02013;3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">2.6 (2.1&#x02013;3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">2.6 (2.1&#x02013;3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">2.7 (2.1&#x02013;3.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Months to SPE<xref rid="TFN5" ref-type="table-fn">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">33.8 (25&#x02013;57)</td><td align="left" valign="top" rowspan="1" colspan="1">33.6 (24&#x02013;54)</td><td align="left" valign="top" rowspan="1" colspan="1">32.0 (24&#x02013;53)</td><td align="left" valign="top" rowspan="1" colspan="1">35.5 (24&#x02013;57)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI at MME, kg/m<sup>2 </sup><xref rid="TFN5" ref-type="table-fn">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">28.0 (26&#x02013;30)</td><td align="left" valign="top" rowspan="1" colspan="1">27.9 (26&#x02013;30)</td><td align="left" valign="top" rowspan="1" colspan="1">27.6 (26&#x02013;30)</td><td align="left" valign="top" rowspan="1" colspan="1">28.1 (26&#x02013;31)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI at SPE, kg/m<sup>2 </sup><xref rid="TFN5" ref-type="table-fn">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">28.9 (27&#x02013;31)</td><td align="left" valign="top" rowspan="1" colspan="1">28.8 (27&#x02013;31)</td><td align="left" valign="top" rowspan="1" colspan="1">28.5 (26&#x02013;31)</td><td align="left" valign="top" rowspan="1" colspan="1">29.1 (27&#x02013;31)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at hire, years<xref rid="TFN5" ref-type="table-fn">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">27 (24&#x02013;29)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (25&#x02013;29)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (25&#x02013;30)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (25&#x02013;29)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at 9/11, years<xref rid="TFN5" ref-type="table-fn">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">40 (36&#x02013;45)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (37&#x02013;46)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (38&#x02013;46)</td><td align="left" valign="top" rowspan="1" colspan="1">40 (36&#x02013;45) <xref rid="TFN6" ref-type="table-fn">ll</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Years of Service at 9/11<xref rid="TFN5" ref-type="table-fn">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">13.9 (7&#x02013;19)</td><td align="left" valign="top" rowspan="1" colspan="1">14.5 (8&#x02013;18)</td><td align="left" valign="top" rowspan="1" colspan="1">15.3 (10&#x02013;20)</td><td align="left" valign="top" rowspan="1" colspan="1">13.1 (7&#x02013;17) <xref rid="TFN6" ref-type="table-fn">ll</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race, Caucasian/African American<xref rid="TFN4" ref-type="table-fn">&#x02021;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">782 (98)/19 (2)</td><td align="left" valign="top" rowspan="1" colspan="1">242 (96)/9 (4)</td><td align="left" valign="top" rowspan="1" colspan="1">121 (96)/5 (4)</td><td align="left" valign="top" rowspan="1" colspan="1">121 (97)/4 (3)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p><italic>Definition of abbreviations:</italic> WTC = World Trade Center; MME = medical monitoring entry; SPE = subspecialty pulmonary evaluation; BMI = body mass index.</p></fn><fn id="TFN2"><label>*</label><p>Arrival at WTC 9/11 Morning,</p></fn><fn id="TFN3"><label>&#x02020;</label><p>Arrival at WTC between noon of 9/11 and midnight of 9/12.</p></fn><fn id="TFN4"><label>&#x02021;</label><p>Expressed as N (%);</p></fn><fn id="TFN5"><label>&#x000a7;</label><p>Values Expressed as Medians (IQR);</p></fn><fn id="TFN6"><label>ll</label><p>p&#x0003c;0.01 by Wilcoxon rank-sum test between cases and controls.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="landscape"><label>Table 2</label><caption><p>Pulmonary Function Testing</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1"/><th valign="middle" align="left" rowspan="1" colspan="1"/><th valign="middle" align="left" rowspan="1" colspan="1">Study Group N=251</th><th valign="middle" align="left" rowspan="1" colspan="1">Controls N=126</th><th valign="middle" align="left" rowspan="1" colspan="1">Cases N=125</th><th valign="middle" align="left" rowspan="1" colspan="1">P-value<xref rid="TFN9" ref-type="table-fn">*</xref></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="5" colspan="1">Pre-9/11 Spirometry</td><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC, %</td><td align="left" valign="top" rowspan="1" colspan="1">84 (81&#x02013;87)</td><td align="left" valign="top" rowspan="1" colspan="1">87 (85&#x02013;89)</td><td align="left" valign="top" rowspan="1" colspan="1">82 (79&#x02013;84)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>, L</td><td align="left" valign="top" rowspan="1" colspan="1">4.3 (3.8&#x02013;4.9)</td><td align="left" valign="top" rowspan="1" colspan="1">4.5 (3.9&#x02013;5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 (3.7&#x02013;4.7)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>, % Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">104 (91&#x02013;115)</td><td align="left" valign="top" rowspan="1" colspan="1">109 (100&#x02013;119)</td><td align="left" valign="top" rowspan="1" colspan="1">93 (86&#x02013;107)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC, L</td><td align="left" valign="top" rowspan="1" colspan="1">5.0 (4.6&#x02013;5.8)</td><td align="left" valign="top" rowspan="1" colspan="1">5.1 (4.5&#x02013;5.8)</td><td align="left" valign="top" rowspan="1" colspan="1">4.9 (4.6&#x02013;5.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.564</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC, % Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">96 (87&#x02013;108)</td><td align="left" valign="top" rowspan="1" colspan="1">100 (91&#x02013;110)</td><td align="left" valign="top" rowspan="1" colspan="1">93 (85&#x02013;106)</td><td align="left" valign="top" rowspan="1" colspan="1">0.011</td></tr><tr><td colspan="6" valign="bottom" align="left" rowspan="1">
<hr/></td></tr><tr><td align="left" valign="middle" rowspan="5" colspan="1">MME Spirometry</td><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC, %</td><td align="left" valign="top" rowspan="1" colspan="1">84 (80&#x02013;87)</td><td align="left" valign="top" rowspan="1" colspan="1">87 (84&#x02013;89)</td><td align="left" valign="top" rowspan="1" colspan="1">81 (77&#x02013;84)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>, L</td><td align="left" valign="top" rowspan="1" colspan="1">3.8 (3.3&#x02013;4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">4.0 (3.6&#x02013;4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3.6 (3.2&#x02013;4.2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>, % Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">92 (81&#x02013;103)</td><td align="left" valign="top" rowspan="1" colspan="1">97 (89&#x02013;107)</td><td align="left" valign="top" rowspan="1" colspan="1">86 (77&#x02013;97)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC, L</td><td align="left" valign="top" rowspan="1" colspan="1">4.6 (4.1&#x02013;5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">4.6 (4.1&#x02013;5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">4.7 (4.1&#x02013;5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.776</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC, % Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">88 (81&#x02013;97)</td><td align="left" valign="top" rowspan="1" colspan="1">90 (82&#x02013;99)</td><td align="left" valign="top" rowspan="1" colspan="1">86 (78&#x02013;95)</td><td align="left" valign="top" rowspan="1" colspan="1">0.034</td></tr><tr><td colspan="6" valign="bottom" align="left" rowspan="1">
<hr/></td></tr><tr><td align="left" valign="middle" rowspan="5" colspan="1">SPE Spirometry</td><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC, %</td><td align="left" valign="top" rowspan="1" colspan="1">76 (73&#x02013;80)</td><td align="left" valign="top" rowspan="1" colspan="1">82 (79&#x02013;84)</td><td align="left" valign="top" rowspan="1" colspan="1">73 (69&#x02013;76)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>, L</td><td align="left" valign="top" rowspan="1" colspan="1">3.8 (3.2&#x02013;4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">4.2 (4.1&#x02013;5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">3.4 (3.0&#x02013;4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>, % Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">95 (76&#x02013;109)</td><td align="left" valign="top" rowspan="1" colspan="1">108 (94&#x02013;114)</td><td align="left" valign="top" rowspan="1" colspan="1">81 (73&#x02013;95)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC, L</td><td align="left" valign="top" rowspan="1" colspan="1">5.0 (4.3&#x02013;5.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5.1 (4.3&#x02013;5.8)</td><td align="left" valign="top" rowspan="1" colspan="1">4.9 (4.3&#x02013;5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.162</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC, % Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">96 (86&#x02013;108)</td><td align="left" valign="top" rowspan="1" colspan="1">101 (89&#x02013;108)</td><td align="left" valign="top" rowspan="1" colspan="1">91 (83&#x02013;103)</td><td align="left" valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td colspan="6" valign="bottom" align="left" rowspan="1">
<hr/></td></tr><tr><td align="left" valign="middle" rowspan="4" colspan="1">SPE Plethysmograph and Diffusion</td><td align="left" valign="top" rowspan="1" colspan="1">TLC% Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">103 (93&#x02013;110)</td><td align="left" valign="top" rowspan="1" colspan="1">102 (85&#x02013;106)</td><td align="left" valign="top" rowspan="1" colspan="1">104 (96&#x02013;112)</td><td align="left" valign="top" rowspan="1" colspan="1">0.031</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FRC% Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">95 (84&#x02013;107)</td><td align="left" valign="top" rowspan="1" colspan="1">86 (72&#x02013;103)</td><td align="left" valign="top" rowspan="1" colspan="1">100 (87&#x02013;114)</td><td align="left" valign="top" rowspan="1" colspan="1">0.212</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RV, % Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">123 (108&#x02013;141)</td><td align="left" valign="top" rowspan="1" colspan="1">114 (98&#x02013;128)</td><td align="left" valign="top" rowspan="1" colspan="1">132 (115&#x02013;157)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DLCO, % Predicted</td><td align="left" valign="top" rowspan="1" colspan="1">107 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">106 (21)</td><td align="left" valign="top" rowspan="1" colspan="1">109 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">0.793</td></tr><tr><td colspan="6" valign="bottom" align="left" rowspan="1">
<hr/></td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">SPE Airway Reactivity</td><td align="left" valign="top" rowspan="1" colspan="1">MCT Slope, % &#x00394;FEV<sub>1</sub>/mg</td><td align="left" valign="top" rowspan="1" colspan="1">0.054 (0.03&#x02013;0.14)</td><td align="left" valign="top" rowspan="1" colspan="1">0.038 (0.02&#x02013;0.07)</td><td align="left" valign="top" rowspan="1" colspan="1">0.092 (0.04&#x02013;0.42)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BD Response, %</td><td align="left" valign="top" rowspan="1" colspan="1">8 (3&#x02013;15)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (2&#x02013;8)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (5&#x02013;18)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><p><italic>Definition of abbreviations</italic>: MME = medical monitoring entry; SPE = subspecialty pulmonary evaluation. MCT = methacholine challenge test</p></fn><fn id="TFN8"><p>All Values Expressed as Median (IQR) or Mean (SD);</p></fn><fn id="TFN9"><label>*</label><p>Significance assessed by Wilcoxon rank-sum test or unpaired Student t-test between cases and controls. SPE Plethysmograph and Diffusion: Total N=121; Controls N=55; Cases N=66. BD Response: Total N=130; Controls N=56; Cases N=74. MCT Slope: Total N=182; Controls N=97; Cases N=85.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Serum Levels of Analytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Serum Analyte</th><th valign="middle" align="left" rowspan="1" colspan="1">Total</th><th valign="middle" align="left" rowspan="1" colspan="1">Controls</th><th valign="middle" align="left" rowspan="1" colspan="1">Cases</th><th valign="middle" align="left" rowspan="1" colspan="1">P-value<xref rid="TFN11" ref-type="table-fn">*</xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Chitotriosidase (ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">29.9 (18&#x02013;46)</td><td align="left" valign="top" rowspan="1" colspan="1">32.2 (20&#x02013;52)</td><td align="left" valign="top" rowspan="1" colspan="1">24.5 (15&#x02013;40)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgE (IU/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">44.6 (17&#x02013;116)</td><td align="left" valign="top" rowspan="1" colspan="1">35.7 (11&#x02013;81)</td><td align="left" valign="top" rowspan="1" colspan="1">50 (24&#x02013;148)</td><td align="left" valign="top" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">YKL-40 (ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">42.1 (30&#x02013;61)</td><td align="left" valign="top" rowspan="1" colspan="1">41.0 (31&#x02013;65)</td><td align="left" valign="top" rowspan="1" colspan="1">44.0 (30&#x02013;59)</td><td align="left" valign="top" rowspan="1" colspan="1">0.621</td></tr></tbody></table><table-wrap-foot><fn id="TFN10"><p>All Values Expressed as Median (IQR);</p></fn><fn id="TFN11"><label>*</label><p>Significance assessed by Wilcoxon rank-sum test between cases and controls.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Analysis Predicting FEV<sub>1</sub>/FVC&#x0003c;LLN at SPE</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Model</th><th valign="middle" align="left" rowspan="1" colspan="1">Predictor</th><th valign="middle" align="left" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="6" colspan="1">Univariable</td><td align="left" valign="top" rowspan="1" colspan="1">Age (yr)</td><td align="left" valign="top" rowspan="1" colspan="1">0.94 (0.90, 0.98)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">1.02 (0.97, 1.08)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Exposure High<xref rid="TFN13" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.68 (0.40, 1.27)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC at MME</td><td align="left" valign="top" rowspan="1" colspan="1">0.78 (0.72, 0.83)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chitotriosidase<xref rid="TFN14" ref-type="table-fn">&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.84 (0.75, 0.94)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgE<xref rid="TFN15" ref-type="table-fn">&#x02021;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">1.23 (1.01, 1.50)</td></tr><tr><td colspan="3" valign="bottom" align="left" rowspan="1">
<hr/></td></tr><tr><td align="left" valign="middle" rowspan="2" colspan="1">Multivariable<xref rid="TFN16" ref-type="table-fn">&#x000a7;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">Chitotriosidase<xref rid="TFN14" ref-type="table-fn">&#x02020;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.82 (0.71, 0.95)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IgE<xref rid="TFN15" ref-type="table-fn">&#x02021;</xref></td><td align="left" valign="top" rowspan="1" colspan="1">1.36 (1.09, 1.71)</td></tr></tbody></table><table-wrap-foot><fn id="TFN12"><p><italic>Definition of abbreviations</italic>: LLN = lower limit of normal; SPE = subspecialty pulmonary evaluation; OR = odds ratio; BMI = body mass index; MME = medical monitoring evaluation.</p></fn><fn id="TFN13"><label>*</label><p>Reference is intermediate exposure group.</p></fn><fn id="TFN14"><label>&#x02020;</label><p>10 ng/mL of Chitotriosidase</p></fn><fn id="TFN15"><label>&#x02021;</label><p>100 IU/mL of IgE.</p></fn><fn id="TFN16"><label>&#x000a7;</label><p>Adjusted for age at 9/11/2001, BMI at SPE, exposure group and FEV<sub>1</sub>/FVC at MME. &#x003c7;<sup>2</sup> (<xref rid="R6" ref-type="bibr">6</xref>) = 49.465, P = &#x0003c;0.001. Hosmer and Lemeshow&#x02019;s goodness-of-fit test P=0.588. Area under ROC curve=0.86.</p></fn></table-wrap-foot></table-wrap></floats-group></article>